Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.GYRE · Entity 5247 | Chief Financial Officer | January 07, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.31 · Expires 2036-01-07 | Direct | 50,000 |
Reported balance
After 2026-01-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 50,000 · Balance 50,000 F1: This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 25% of which will vest on January 7, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 25% of which will vest on January 7, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2026 Filed Jan 9, 2026 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001140361-26-000831 · form4.xml · derivative · entry 1 Chen Ruoyu · CIK 0001982080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-01-07 F1 · derivative.exercise_date: This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 25% of which will vest on January 7, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 14, 2024 Filed Aug 17, 2024 00:53 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.98 | $0.00 |
DisclosureSEC source: 0001140361-24-037706 · form4.xml · derivative · entry 1 Chen Ruoyu · CIK 0001982080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-08-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 25% of which will vest on August 14, 2025, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 20, 2023 Filed Nov 23, 2023 00:34 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 578,540 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-23-054516 · form4.xml · derivative · entry 1 Chen Ruoyu · CIK 0001982080 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 578,540 Underlying: Common Stock · 578,540 shares Expires 2030-10-31 F1 · derivative.exercise_price: Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. F1 · derivative.exercise_date: Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. F2 · derivative.exercise_date: These options are vested in full. F1 · derivative.expiration_date: Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. Read SEC document |
| October 31, 2023 Filed Nov 1, 2023 10:15 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 34,380 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-23-050617 · form4.xml · derivative · entry 1 Chen Ruoyu · CIK 0001982080 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,380 Underlying: Common Stock · 34,380 shares Expires 2033-10-31 F1 · derivative.exercise_date: These options are vested in full. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.